Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27925869 | 0.85 | SCN9A (0.49) | EGLN1MAP4K4HIF1ACYP2A6USP7 | |
| SCHEMBL18015585 | 0.82 | P4HTM (0.50) | P4HTMMAP4K4P4HA1MIFKDM4E | |
| SCHEMBL27772735 | 0.81 | MAPK1 (0.53) | EGLN1HIF1AUSP7EGLN3KDM4E | |
| SCHEMBL4781819 | 0.80 | MAP4K4 (0.59) | MAP4K4GCGRPTGS2 | |
| SCHEMBL71034 | 0.80 | HIF1A (0.55) | P4HTMMAP4K4HIF1AP4HA1MIF | |
| SCHEMBL29929320 | 0.80 | HIF1A (0.55) | P4HTMMAP4K4HIF1AP4HA1MIF | |
| SCHEMBL4777265 | 0.79 | HIF1A (0.57) | P4HTMMAP4K4HIF1AP4HA1MIF | |
| SCHEMBL13731115 | 0.79 | P4HTM (0.64) | EGLN1P4HTMMAP4K4HIF1AP4HA1 | |
| SCHEMBL4182641 | 0.79 | CNR2 (0.49) | EGLN1P4HTMMAP4K4HIF1AP4HA1 | |
| Hydrochloric Acid SCHEMBL28470042 | 0.78 | HIF1A (0.54) | P4HTMMAP4K4HIF1AP4HA1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| EP-1575918-A2 | SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004056774-A2 | SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-08 | — | — | WO | claimed |
| CN-101981008-B | 5, 6-diaryl-pyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof as urotensin II receptor antagonists | SANOFI AVENTIS | 2013-07-31 | — | — | CN | disclosed |
| CN-101981008-A | 5, 6-diaryl-pyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof as urotensin II receptor antagonists | SANOFI AVENTIS | 2011-02-23 | — | — | CN | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
| EP-1575918-A2 | SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056774-A2 | SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | EGLN1 506/4885P4HTM 223/4885MAP4K4 2682/4885 |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | EGLN1 1644/4885P4HTM 642/4885MAP4K4 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.